EU5 Neuromodulation Devices Market Outlook to 2033 - Implantable Neuromodulation Devices and Non-Invasive Neuromodulation Devices

Description

List of Tables

GlobalData's "EU5 Neuromodulation Devices Outlook to 2033" is a comprehensive databook report, covering key market data on the EU5 Neuromodulation Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Implantable Neuromodulation Devices, Minimally Invasive Neuromodulation Devices and Non-Invasive Neuromodulation Devices

The EU5 Neuromodulation Devices Market report provides key information and data on -

Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2025 company share data for Neuromodulation Devices Market.
Global corporate-level profiles of key companies operating within the EU5 Neuromodulation Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

EU5 Neuromodulation Devices is segmented as follows -

Implantable Neuromodulation Devices
Minimally Invasive Neuromodulation Devices
Non-Invasive Neuromodulation Devices

Reasons to Buy

The EU5 Neuromodulation Devices Market report helps you to develop -

Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Product Code: GDME21759CRDB

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 What Is This Report About?
2.2 Neuromodulation Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report

3 Neuromodulation Devices Market, EU5

3.1 Neuromodulation Devices Market, EU5, Revenue ($m), 2018-2033
3.2 Neuromodulation Devices Market, EU5, Revenue ($m), 2018-2033
3.3 Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033
3.4 Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033
3.5 Neuromodulation Devices Market, EU5, Company Share by Revenue ($m), 2025

4 Neuromodulation Devices Market, France

4.1 Neuromodulation Devices Market, France, Revenue ($m), 2018-2033
- 4.1.1 Implantable Neuromodulation Devices Market, France, Revenue ($m), by Segment, 2018-2033
4.2 Neuromodulation Devices Market, France, Volume (Units), 2018-2033
- 4.2.1 Implantable Neuromodulation Devices Market, France, Volume (Units), by Segment, 2018-2033
4.3 Neuromodulation Devices Market, France, Average Price ($), 2018-2033
4.4 Neuromodulation Devices Market, France, Company Share by Revenue ($m), 2025

5 Neuromodulation Devices Market, Germany

5.1 Neuromodulation Devices Market, Germany, Revenue ($m), 2018-2033
- 5.1.1 Implantable Neuromodulation Devices Market, Germany, Revenue ($m), by Segment, 2018-2033
5.2 Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033
- 5.2.1 Implantable Neuromodulation Devices Market, Germany, Volume (Units), by Segment, 2018-2033
5.3 Neuromodulation Devices Market, Germany, Average Price ($), 2018-2033
5.4 Neuromodulation Devices Market, Germany, Company Share by Revenue ($m), 2025

6 Neuromodulation Devices Market, Italy

6.1 Neuromodulation Devices Market, Italy, Revenue ($m), 2018-2033
- 6.1.1 Implantable Neuromodulation Devices Market, Italy, Revenue ($m), by Segment, 2018-2033
6.2 Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033
- 6.2.1 Implantable Neuromodulation Devices Market, Italy, Volume (Units), by Segment, 2018-2033
6.3 Neuromodulation Devices Market, Italy, Average Price ($), 2018-2033
6.4 Neuromodulation Devices Market, Italy, Company Share by Revenue ($m), 2025

7 Neuromodulation Devices Market, Spain

7.1 Neuromodulation Devices Market, Spain, Revenue ($m), 2018-2033
- 7.1.1 Implantable Neuromodulation Devices Market, Spain, Revenue ($m), by Segment, 2018-2033
7.2 Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033
- 7.2.1 Implantable Neuromodulation Devices Market, Spain, Volume (Units), by Segment, 2018-2033
7.3 Neuromodulation Devices Market, Spain, Average Price ($), 2018-2033
7.4 Neuromodulation Devices Market, Spain, Company Share by Revenue ($m), 2025

8 Neuromodulation Devices Market, United Kingdom

8.1 Neuromodulation Devices Market, United Kingdom, Revenue ($m), 2018-2033
- 8.1.1 Implantable Neuromodulation Devices Market, United Kingdom, Revenue ($m), by Segment, 2018-2033
8.2 Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033
- 8.2.1 Implantable Neuromodulation Devices Market, United Kingdom, Volume (Units), by Segment, 2018-2033
8.3 Neuromodulation Devices Market, United Kingdom, Average Price ($), 2018-2033
8.4 Neuromodulation Devices Market, United Kingdom, Company Share by Revenue ($m), 2025

9 Overview of Key Companies in EU5 Neuromodulation Devices Market

9.1 Medtronic Plc
- 9.1.1 Company Overview
9.2 Boston Scientific Corp
- 9.2.1 Company Overview
9.3 Abbott Laboratories
- 9.3.1 Company Overview
9.4 LivaNova Plc
- 9.4.1 Company Overview
9.5 Nevro Corp
- 9.5.1 Company Overview
9.6 Enterra Medical Inc
- 9.6.1 Company Overview
9.7 Axonics Inc
- 9.7.1 Company Overview

10 Neuromodulation Devices Market Pipeline Products

11 Recent Developments

11.1 Corporate Communications
- 11.1.1 Nov 11, 2025: Novel Technique Enhances Brain-State Detection
- 11.1.2 Nov 05, 2025: Waardenburg Syndrome and Piebaldism
- 11.1.3 Nov 04, 2025: CSIC Receives Two Technological Prototypes from CDTI for Neurological Disease Therapies
- 11.1.4 Nov 03, 2025: Neurovalens Secures £6m Funding
- 11.1.5 Oct 29, 2025: Neurosurgery Clinic of SZU and UNB Pioneers Minimally Invasive Treatment of Brain Hemorrhage in Central Europe
- 11.1.6 Oct 23, 2025: New MRgFUS Machine Supported With 5 Million Kroner
- 11.1.7 Oct 21, 2025: New Electrode System Provides Insights into Spinal Cord Function
- 11.1.8 Oct 16, 2025: IXICO CEO Bram Goorden Discusses Strong 2025 Performance And 2026 Priorities
- 11.1.9 Oct 06, 2025: GSK Appoints Luke Miels As CEO Designate
- 11.1.10 Sep 19, 2025: SensoDetect Strengthens Global Clinical Leadership: Dr. Mohamed Hussein Atwa Ahmed Now Permanently Based in Sweden to Drive Expansion and Investor Value
- 11.1.11 Sep 16, 2025: Sant Pau Integrates Hifu in New Brain Neuromodulation Unit
- 11.1.12 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces
- 11.1.13 Sep 08, 2025: Changes To The Executive Board Of Carl Zeiss AG
- 11.1.14 Sep 08, 2025: Immunotherapy Before Surgery Shows Promise for Rare Lung Cancer Treatment
- 11.1.15 Aug 19, 2025: Medtronic Appoints John Groetelaars and Bill Jellison as Independent Directors
- 11.1.16 Jul 08, 2025: Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed
- 11.1.17 Jun 24, 2025: GSK Announces Director Declaration
- 11.1.18 Jun 09, 2025: Nottinghamshire Healthcare receives funding for infrastructure improvements
- 11.1.19 May 21, 2025: Medtronic Announces Leadership Change in Cardiovascular Portfolio
- 11.1.20 Mar 25, 2025: CorTec Names Frank Desiere as Chief Executive Officer
11.2 Financial Announcements
- 11.2.1 Jan 29, 2026: Sanofi Releases 2025 Strong Sales and EPS Growth
- 11.2.2 Sep 02, 2025: Boston Scientific Announces 2025 Investor Day Meeting and Conference Call Discussing Third Quarter 2025 Results
- 11.2.3 Jul 31, 2025: Sanofi Q2: Double-Digit Sales and Solid Business EPS Growth
- 11.2.4 Jul 24, 2025: Avanos Medical to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
- 11.2.5 May 07, 2025: Medtronic to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2025
11.3 Government and Public Interest
- 11.3.1 Sep 30, 2025: Sequana Medical Features Alfapump System at 2025 Portal Intervention Symposium
- 11.3.2 Sep 02, 2025: Compelling Data at ESC Congress 2025 Reinforce Safety and Performance of the Medtronic Omniasecure Defibrillation Lead, Including in the Left Bundle Branch Area
- 11.3.3 Aug 29, 2025: Medtronic Executives to Speak at Upcoming Investor Conferences
- 11.3.4 Aug 22, 2025: LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
- 11.3.5 May 23, 2025: Medtronic Chairman and CEO Geoff Martha to Speak at Bernstein's Strategic Decisions Conference
11.4 Other Significant Developments
- 11.4.1 Jan 29, 2026: Sanofi Releases 2025 Strong Sales and EPS Growth
- 11.4.2 Nov 21, 2025: Sant Pau Incorporates Transcranial Magnetic Stimulation Device With Help From Asuncion Llaurado de Febrer Foundation
- 11.4.3 Nov 20, 2025: Nexstim Receives NBS 6 System Order From New Research Customer
- 11.4.4 Nov 04, 2025: CSIC Receives Two Technological Prototypes from CDTI for Neurological Disease Therapies
- 11.4.5 Nov 03, 2025: Cefaly Achieves Milestone as Most Prescribed Neuromodulation Device by Veterans Health Administration
- 11.4.6 Oct 29, 2025: Neurosurgery Clinic of SZU and UNB Pioneers Minimally Invasive Treatment of Brain Hemorrhage in Central Europe
- 11.4.7 Oct 27, 2025: Nexstim Receives Order for NBS 6 System from Finnish Hospital
- 11.4.8 Oct 16, 2025: IXICO CEO Bram Goorden Discusses Strong 2025 Performance And 2026 Priorities
- 11.4.9 Oct 14, 2025: Nexstim Secures Order for NBS 6 Therapy System from Private Medical Center in Finland
- 11.4.10 Oct 13, 2025: Onward Medical Provides Q3 2025 Update on ARC-EX Adoption
- 11.4.11 Oct 07, 2025: Nexstim Receives System Order From US Clinic
- 11.4.12 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington
- 11.4.13 Jul 31, 2025: Sanofi Q2: Double-Digit Sales and Solid Business EPS Growth
11.5 Product News
- 11.5.1 Jan 14, 2026: TOXINS 2026: Clinical Updates on Galderma's Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
- 11.5.2 Nov 21, 2025: Brainbox and Sonic Concepts Deliver 100 NeuroFUS Systems Worldwide
- 11.5.3 Nov 21, 2025: Sant Pau Incorporates Transcranial Magnetic Stimulation Device With Help From Asuncion Llaurado de Febrer Foundation
- 11.5.4 Nov 17, 2025: BrainsWay Launches Clinical Trial of Deep TMS 360 System for Alcohol Use Disorder
- 11.5.5 Nov 05, 2025: MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer's Patients
- 11.5.6 Nov 03, 2025: Cefaly Achieves Milestone as Most Prescribed Neuromodulation Device by Veterans Health Administration
- 11.5.7 Nov 03, 2025: Neurovalens Secures £6m Funding
- 11.5.8 Oct 31, 2025: European Investment Bank Supports German MedTech with €20 Million for PRECISIS
- 11.5.9 Oct 31, 2025: New Project Aims to Transform Implantable Medical Devices
- 11.5.10 Oct 30, 2025: Sant Pau Incorporates MRgFUS Technology For Movement Disorders Without Surgery
- 11.5.11 Oct 27, 2025: Nexstim Receives Order for NBS 6 System from Finnish Hospital
- 11.5.12 Oct 21, 2025: New Electrode System Provides Insights into Spinal Cord Function
- 11.5.13 Oct 20, 2025: Neupulse Attends Launch of N3 Centre for Neurotechnology
- 11.5.14 Oct 16, 2025: First Brain-Computer Interface Implantation for Paralysis in Europe
- 11.5.15 Oct 14, 2025: Nexstim Secures Order for NBS 6 Therapy System from Private Medical Center in Finland
- 11.5.16 Oct 13, 2025: Onward Medical Provides Q3 2025 Update on ARC-EX Adoption
- 11.5.17 Sep 30, 2025: Sequana Medical Features Alfapump System at 2025 Portal Intervention Symposium
- 11.5.18 Sep 19, 2025: Medtronic Receives FDA Approval for Altaviva Device to Treat Urge Urinary Incontinence
- 11.5.19 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington
- 11.5.20 Sep 16, 2025: Sant Pau Integrates Hifu in New Brain Neuromodulation Unit
- 11.5.21 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces
- 11.5.22 Sep 10, 2025: Neurocare Group's Apollo TMS Therapy Devices Granted FDA Clearance for Treating Adolescent Depression
- 11.5.23 Sep 08, 2025: Onward Medical Receives CE Mark for Arc-Ex, Enabling Commercial Launch in Europe
- 11.5.24 May 28, 2025: Nyxoah to Present at the Jefferies Global Healthcare Conference
- 11.5.25 May 27, 2025: CEFALY Technology Announces Launch of CEFALY@Work
11.6 Strategy And Business Planning
- 11.6.1 Nov 24, 2025: Johnson & Johnson Expands Neurovascular Research and Development Activities in Galway
- 11.6.2 Nov 21, 2025: Brainbox and Sonic Concepts Deliver 100 NeuroFUS Systems Worldwide
- 11.6.3 Nov 13, 2025: Partnership Enhances Patient Access to Neurotechnologies
- 11.6.4 Nov 10, 2025: Inbrain Neuroelectronics Collaborates With Microsoft to Enhance Agentic AI for Neurology and Brain-Computer Interfaces
- 11.6.5 Nov 06, 2025: Medical University of Innsbruck Joins NeurotechEU Alliance
- 11.6.6 Nov 04, 2025: Zeiss Opens New Quality Excellence Center in Connecticut
- 11.6.7 Nov 03, 2025: Neurovalens Secures £6m Funding
- 11.6.8 Oct 31, 2025: European Investment Bank Supports German MedTech with €20 Million for PRECISIS
- 11.6.9 Oct 20, 2025: Neupulse Attends Launch of N3 Centre for Neurotechnology
- 11.6.10 Oct 16, 2025: IXICO CEO Bram Goorden Discusses Strong 2025 Performance And 2026 Priorities
- 11.6.11 Sep 18, 2025: Panaxium Research Signs Exclusive IP Agreement With University of Washington
- 11.6.12 Sep 15, 2025: Inbrain Neuroelectronics Collaborates to Enhance Graphene-Based Brain-Computer Interfaces

12 Appendix

12.1 Research Methodology
- 12.1.1 Coverage
- 12.1.2 Secondary Research
- 12.1.3 Primary Research
- 12.1.4 Market Modeling and Forecasting
- 12.1.5 Company Share Analysis
- 12.1.6 Benchmarking
12.2 GlobalData Consulting
12.3 Contact Us
12.4 Disclaimer

Product Code: GDME21759CRDB

List of Table

List of Tables

Table 1: Neuromodulation Devices Market, Cross Country Comparison, EU5, Revenue ($m), USD Constant, 2018-2033
Table 2: Neuromodulation Devices Market, EU5, Revenue ($m), USD Constant, 2018-2033
Table 3: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033
Table 4: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033
Table 5: Neuromodulation Devices Market, EU5, Company Share by Revenue ($m), 2025
Table 6: Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033
Table 7: Implantable Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033
Table 8: Neuromodulation Devices Market, France, Volume (Units), 2018-2033
Table 9: Implantable Neuromodulation Devices Market, France, Volume (Units), 2018-2033
Table 10: Neuromodulation Devices Market, France, Average Price ($), 2018-2033
Table 11: Neuromodulation Devices Market, France, Company Share by Revenue ($m), 2025
Table 12: Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033
Table 13: Implantable Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033
Table 14: Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033
Table 15: Implantable Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033
Table 16: Neuromodulation Devices Market, Germany, Average Price ($), 2018-2033
Table 17: Neuromodulation Devices Market, Germany, Company Share by Revenue ($m), 2025
Table 18: Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033
Table 19: Implantable Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033
Table 20: Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033
Table 21: Implantable Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033
Table 22: Neuromodulation Devices Market, Italy, Average Price ($), 2018-2033
Table 23: Neuromodulation Devices Market, Italy, Company Share by Revenue ($m), 2025
Table 24: Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 25: Implantable Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033
Table 26: Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033
Table 27: Implantable Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033
Table 28: Neuromodulation Devices Market, Spain, Average Price ($), 2018-2033
Table 29: Neuromodulation Devices Market, Spain, Company Share by Revenue ($m), 2025
Table 30: Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Table 31: Implantable Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Table 32: Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033
Table 33: Implantable Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033
Table 34: Neuromodulation Devices Market, United Kingdom, Average Price ($), 2018-2033
Table 35: Neuromodulation Devices Market, United Kingdom, Company Share by Revenue ($m), 2025
Table 36: Neuromodulation Devices Market Pipeline Products
Table 37: Total Number of Primary Research Participants, Neurology Devices Market, by Country

List of Figure

List of Figures

Figure 1: Neuromodulation Devices Market, Cross Country Comparison, EU5, Revenue ($m), USD Constant, 2018-2033
Figure 2: Neuromodulation Devices Market, EU5, Revenue ($m), USD Constant, 2018-2033
Figure 3: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033
Figure 4: Neuromodulation Devices Market, EU5, Volume (Units), 2018-2033
Figure 5: Neuromodulation Devices Market, EU5, Company Share (%), 2025
Figure 6: Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033
Figure 7: Implantable Neuromodulation Devices Market, France, Revenue ($m), USD Constant, 2018-2033
Figure 8: Neuromodulation Devices Market, France, Volume (Units), 2018-2033
Figure 9: Implantable Neuromodulation Devices Market, France, Volume (Units), 2018-2033
Figure 10: Neuromodulation Devices Market, France, Company Share (%), 2025
Figure 11: Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033
Figure 12: Implantable Neuromodulation Devices Market, Germany, Revenue ($m), USD Constant, 2018-2033
Figure 13: Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033
Figure 14: Implantable Neuromodulation Devices Market, Germany, Volume (Units), 2018-2033
Figure 15: Neuromodulation Devices Market, Germany, Company Share (%), 2025
Figure 16: Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033
Figure 17: Implantable Neuromodulation Devices Market, Italy, Revenue ($m), USD Constant, 2018-2033
Figure 18: Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033
Figure 19: Implantable Neuromodulation Devices Market, Italy, Volume (Units), 2018-2033
Figure 20: Neuromodulation Devices Market, Italy, Company Share (%), 2025
Figure 21: Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 22: Implantable Neuromodulation Devices Market, Spain, Revenue ($m), USD Constant, 2018-2033
Figure 23: Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033
Figure 24: Implantable Neuromodulation Devices Market, Spain, Volume (Units), 2018-2033
Figure 25: Neuromodulation Devices Market, Spain, Company Share (%), 2025
Figure 26: Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Figure 27: Implantable Neuromodulation Devices Market, United Kingdom, Revenue ($m), USD Constant, 2018-2033
Figure 28: Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033
Figure 29: Implantable Neuromodulation Devices Market, United Kingdom, Volume (Units), 2018-2033
Figure 30: Neuromodulation Devices Market, United Kingdom, Company Share (%), 2025